JP2013525330A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013525330A5 JP2013525330A5 JP2013505466A JP2013505466A JP2013525330A5 JP 2013525330 A5 JP2013525330 A5 JP 2013525330A5 JP 2013505466 A JP2013505466 A JP 2013505466A JP 2013505466 A JP2013505466 A JP 2013505466A JP 2013525330 A5 JP2013525330 A5 JP 2013525330A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- conjugate
- reuptake inhibitor
- serotonin
- norepinephrine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 Cc1cc(C(C(*)(*)C2(*)**(*N*)C3=O)c4ccccc4C2N3I)ccc1 Chemical compound Cc1cc(C(C(*)(*)C2(*)**(*N*)C3=O)c4ccccc4C2N3I)ccc1 0.000 description 3
- YVVVQVSPNGMJAX-QCDSWUKFSA-N CN([C@@H](CC1)c2ccccc2[C@@H]1c(cc1)cc(Cl)c1Cl)C(CCCCCNC(CCC(NCCCCCCOP(O)(O)=O)=O)=O)=O Chemical compound CN([C@@H](CC1)c2ccccc2[C@@H]1c(cc1)cc(Cl)c1Cl)C(CCCCCNC(CCC(NCCCCCCOP(O)(O)=O)=O)=O)=O YVVVQVSPNGMJAX-QCDSWUKFSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32551510P | 2010-04-19 | 2010-04-19 | |
| EP10382087.4 | 2010-04-19 | ||
| US61/325,515 | 2010-04-19 | ||
| EP10382087A EP2380595A1 (en) | 2010-04-19 | 2010-04-19 | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types |
| EP11382031 | 2011-02-09 | ||
| EP11382031.0 | 2011-02-09 | ||
| PCT/EP2011/056270 WO2011131693A2 (en) | 2010-04-19 | 2011-04-19 | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013525330A JP2013525330A (ja) | 2013-06-20 |
| JP2013525330A5 true JP2013525330A5 (enExample) | 2014-06-19 |
| JP5819401B2 JP5819401B2 (ja) | 2015-11-24 |
Family
ID=44063382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013505466A Active JP5819401B2 (ja) | 2010-04-19 | 2011-04-19 | 組成物及びオリゴヌクレオチド分子を特異的なニューロンのタイプに選択的に送達する方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9193969B2 (enExample) |
| EP (2) | EP2560687B1 (enExample) |
| JP (1) | JP5819401B2 (enExample) |
| KR (1) | KR20130103662A (enExample) |
| AR (1) | AR083715A1 (enExample) |
| AU (4) | AU2011244321A1 (enExample) |
| BR (1) | BR112012026471A2 (enExample) |
| CA (1) | CA2796722C (enExample) |
| DK (1) | DK2560687T3 (enExample) |
| ES (1) | ES2638309T3 (enExample) |
| LT (1) | LT2560687T (enExample) |
| MX (1) | MX342764B (enExample) |
| RU (1) | RU2664452C2 (enExample) |
| WO (1) | WO2011131693A2 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2496493T3 (es) | 2002-01-11 | 2014-09-19 | Bioasis Technologies Inc. | Uso de p97 como sistema de administración de enzimas para la administración de enzimas lisosómicas terapéuticas |
| LT2560687T (lt) | 2010-04-19 | 2017-09-25 | Nlife Therapeutics S.L. | Kompozicijos ir būdai, skirti selektyviam oligonukleotido molekulių pristatymui specifiniams neuronų tipams |
| WO2012068405A2 (en) | 2010-11-17 | 2012-05-24 | Isis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
| PT2717917T (pt) | 2011-07-05 | 2016-07-27 | Bioasis Technologies Inc | Conjugados de anticorpos p97 |
| CA2844012C (en) | 2011-08-04 | 2021-03-16 | Yeda Research And Development Co. Ltd. | Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions |
| EP2788087A4 (en) * | 2011-12-06 | 2015-08-26 | Ohio State Innovation Foundation | Non-ionic, low-osmolar contrast agents for the administration of antisense oligonucleotides and the treatment of diseases |
| WO2013148283A1 (en) | 2012-03-30 | 2013-10-03 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome |
| US9932565B2 (en) | 2012-07-31 | 2018-04-03 | Bioasis Technologies, Inc. | Dephosphorylated lysosomal storage disease proteins and methods of use thereof |
| EP2911697A1 (en) | 2012-10-26 | 2015-09-02 | Nlife Therapeutics S.L. | Compositions and methods for selective delivery of oligonucleotide molecules to cell types |
| ES2967530T3 (es) | 2012-10-26 | 2024-04-30 | Palomo Ltd | Composiciones y métodos para el tratamiento de la enfermedad de Parkinson mediante la administración selectiva de moléculas de oligonucleótidos a tipos específicos de neuronas |
| SG10201804331TA (en) | 2012-11-15 | 2018-07-30 | Roche Innovation Ct Copenhagen As | Oligonucleotide conjugates |
| EP2743695A1 (en) | 2012-12-12 | 2014-06-18 | Nanogap Sub NM Powder, S.A. | Methods and reagents for the detection of biomolecules using luminescence |
| EP2970433B1 (en) | 2013-03-13 | 2019-09-18 | Bioasis Technologies Inc. | Fragments of p97 and uses thereof |
| CN111254145A (zh) | 2013-03-14 | 2020-06-09 | Ionis制药公司 | 用于调节tau表达的组合物和方法 |
| JP6276390B2 (ja) * | 2013-05-21 | 2018-02-07 | 成都先導薬物開発有限公司 | 化合物の細胞膜透過の方法 |
| JP6262848B2 (ja) * | 2013-05-21 | 2018-01-17 | 成都先導薬物開発有限公司 | 薬物標的の捕獲方法 |
| WO2014187315A1 (zh) * | 2013-05-21 | 2014-11-27 | 成都先导药物开发有限公司 | 一种化合物给药前体及药物载体制剂 |
| TWI657819B (zh) | 2013-07-19 | 2019-05-01 | 美商Ionis製藥公司 | 用於調節τ蛋白表現之組合物 |
| JP6603227B2 (ja) | 2014-02-03 | 2019-11-06 | バイオアシス テクノロジーズ インコーポレイテッド | Ｐ９７融合タンパク質 |
| CN106715695B (zh) | 2014-02-05 | 2020-07-31 | 耶达研究及发展有限公司 | 用于治疗和诊断的微rna和包含所述微rna的组合物 |
| ES2762672T3 (es) | 2014-02-19 | 2020-05-25 | Bioasis Technologies Inc | Proteínas de fusión de P97-IDS |
| WO2015168521A2 (en) * | 2014-05-01 | 2015-11-05 | Bioasis Technologies, Inc. | P97-polynucleotide conjugates |
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| EP3201339A4 (en) | 2014-10-03 | 2018-09-19 | Cold Spring Harbor Laboratory | Targeted augmentation of nuclear gene output |
| WO2017015575A1 (en) | 2015-07-22 | 2017-01-26 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| US10733023B1 (en) * | 2015-08-06 | 2020-08-04 | D2Iq, Inc. | Oversubscription scheduling |
| ES2753274T5 (es) * | 2015-08-21 | 2023-05-26 | 42 Life Sciences Gmbh & Co Kg | Composición y procedimiento de hibridación |
| AU2016334804B2 (en) | 2015-10-09 | 2022-03-31 | University Of Southampton | Modulation of gene expression and screening for deregulated protein expression |
| ES2882500T3 (es) | 2015-12-14 | 2021-12-02 | Cold Spring Harbor Laboratory | Oligómeros antisentido para el tratamiento del síndrome de Dravet |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| GB2574525B (en) * | 2015-12-21 | 2020-09-02 | Sutura Therapeutics Ltd | Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides |
| GB2545898B (en) | 2015-12-21 | 2019-10-09 | Sutura Therapeutics Ltd | Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides |
| US20190240346A1 (en) * | 2016-06-20 | 2019-08-08 | Genahead Bio, Inc. | Antibody-drug conjugate |
| KR101916652B1 (ko) * | 2016-06-29 | 2018-11-08 | 올릭스 주식회사 | 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도 |
| US10208098B2 (en) * | 2016-09-15 | 2019-02-19 | Council Of Scientific & Industrial Research | Recombinant protein-based method for the delivery of silencer RNA to target the brain |
| ES2963428T3 (es) | 2016-09-29 | 2024-03-27 | Biogen Ma Inc | Compuestos y métodos para reducir la expresión de Tau |
| SI3673080T1 (sl) | 2017-08-25 | 2024-03-29 | Stoke Therapeutics, Inc. | Protismiselni oligomeri za zdravljenje bolezenskih stanj in bolezni |
| WO2019060613A2 (en) | 2017-09-22 | 2019-03-28 | John Mansell | COMPOSITIONS AND METHODS FOR TREATING SEPSIS-RELATED DISORDERS |
| EP3461487A1 (en) * | 2017-09-29 | 2019-04-03 | Nlife Therapeutics S.L. | Compositions and methods for the delivery of mrna to hepatic cells |
| EP3700570B1 (en) | 2017-10-23 | 2025-01-08 | Stoke Therapeutics, Inc. | Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases |
| EA202091012A1 (ru) | 2017-10-25 | 2020-08-27 | Янссен Фармасьютикалз, Инк. | Композиции фосфорилированных тау-пептидов и их применения |
| TWI809004B (zh) | 2017-11-09 | 2023-07-21 | 美商Ionis製藥公司 | 用於降低snca表現之化合物及方法 |
| CN120310791A (zh) | 2018-01-12 | 2025-07-15 | 百时美施贵宝公司 | 靶向α-突触核蛋白的反义寡核苷酸及其用途 |
| MA51634A (fr) | 2018-01-12 | 2020-11-18 | Roche Innovation Ct Copenhagen As | Oligonucléotides antisens d'alpha-synucléine et leurs utilisations |
| US12241065B2 (en) | 2018-01-12 | 2025-03-04 | Bristol-Myers Squibb Company | Antisense oligonucleotides targeting alpha-synuclein and uses thereof |
| WO2019213525A1 (en) | 2018-05-04 | 2019-11-07 | Stoke Therapeutics, Inc. | Methods and compositions for treatment of cholesteryl ester storage disease |
| CN120795059A (zh) | 2018-08-27 | 2025-10-17 | 瑞泽恩制药公司 | 拉曼光谱在下游纯化中的应用 |
| ES2698565B2 (es) * | 2018-12-12 | 2019-07-16 | Univ Madrid Complutense | Procedimiento para la elaboración de nanopartículas lipídicas, y nanopartículas lipídicas con los macrófagos cerebrales como células diana |
| CN113710269A (zh) | 2019-02-08 | 2021-11-26 | Ac免疫有限公司 | 磷酸化Tau肽疫苗的安全施用方法 |
| KR20210134003A (ko) | 2019-02-27 | 2021-11-08 | 스톡 테라퓨틱스, 인크. | 병태 및 질환의 치료를 위한 안티센스 올리고머 |
| EP3952919A2 (en) | 2019-04-11 | 2022-02-16 | Northeastern University | Oligonucleotide-polymer miktoarm conjugates and methods of use |
| EP3983077A4 (en) * | 2019-06-17 | 2023-12-20 | Alnylam Pharmaceuticals, Inc. | DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM |
| BR112022022889A2 (pt) | 2020-05-11 | 2023-04-04 | Stoke Therapeutics Inc | Oligômeros antissentido de opa1 para tratamento de condições e doenças |
| EP4277635A4 (en) * | 2021-01-18 | 2024-12-25 | Yeda Research and Development Co. Ltd | MODIFIED MIR-135, CONJUGATED FORM THEREOF, AND USES THEREOF |
| WO2024069229A2 (en) | 2022-08-03 | 2024-04-04 | Sutura Therapeutics Ltd | Biologically active compounds |
| US12396981B2 (en) | 2023-03-09 | 2025-08-26 | William Shulman | Methods of using DMT |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040242594A1 (en) * | 2001-11-17 | 2004-12-02 | Dan Peters | Prodrugs of antidepressants and their use for treating depressions |
| EP1336406A1 (en) * | 2002-02-14 | 2003-08-20 | Solvay Pharmaceuticals B.V. | Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity |
| JP2007525211A (ja) * | 2004-01-19 | 2007-09-06 | テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド | パーキンソン病の診断検査 |
| WO2007050789A2 (en) * | 2005-10-25 | 2007-05-03 | Nëdken Corporation | Glycosyl-oligonucleotide conjugates and methods |
| GB0605337D0 (en) | 2006-03-17 | 2006-04-26 | Genomica Sau | Treatment of CNS conditions |
| WO2008033285A2 (en) * | 2006-09-15 | 2008-03-20 | The Trustees Of Culumbia University In The City Of New York | Delivery of double-stranded rna into the central nervous system |
| MX2010006925A (es) * | 2007-12-20 | 2011-05-02 | Angiochem Inc | Conjugados de polipeptido-acido nucleico y sus usos. |
| GB0809476D0 (en) * | 2008-05-23 | 2008-07-02 | Cambridge Entpr Ltd | Treatment of neurodegenerative disorders |
| DE102009058769A1 (de) * | 2009-12-16 | 2011-06-22 | MagForce Nanotechnologies AG, 10589 | Temperaturabhängige Aktivierung von katalytischen Nukleinsäuren zur kontrollierten Wirkstofffreisetzung |
| LT2560687T (lt) | 2010-04-19 | 2017-09-25 | Nlife Therapeutics S.L. | Kompozicijos ir būdai, skirti selektyviam oligonukleotido molekulių pristatymui specifiniams neuronų tipams |
| WO2012068405A2 (en) * | 2010-11-17 | 2012-05-24 | Isis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
| ES2967530T3 (es) | 2012-10-26 | 2024-04-30 | Palomo Ltd | Composiciones y métodos para el tratamiento de la enfermedad de Parkinson mediante la administración selectiva de moléculas de oligonucleótidos a tipos específicos de neuronas |
| EP2911697A1 (en) | 2012-10-26 | 2015-09-02 | Nlife Therapeutics S.L. | Compositions and methods for selective delivery of oligonucleotide molecules to cell types |
-
2011
- 2011-04-19 LT LTEP11718678.3T patent/LT2560687T/lt unknown
- 2011-04-19 ES ES11718678.3T patent/ES2638309T3/es active Active
- 2011-04-19 AU AU2011244321A patent/AU2011244321A1/en not_active Abandoned
- 2011-04-19 MX MX2012012214A patent/MX342764B/es active IP Right Grant
- 2011-04-19 DK DK11718678.3T patent/DK2560687T3/en active
- 2011-04-19 EP EP11718678.3A patent/EP2560687B1/en active Active
- 2011-04-19 JP JP2013505466A patent/JP5819401B2/ja active Active
- 2011-04-19 WO PCT/EP2011/056270 patent/WO2011131693A2/en not_active Ceased
- 2011-04-19 CA CA2796722A patent/CA2796722C/en active Active
- 2011-04-19 KR KR1020127030202A patent/KR20130103662A/ko not_active Ceased
- 2011-04-19 RU RU2012149042A patent/RU2664452C2/ru active
- 2011-04-19 EP EP17172370.3A patent/EP3231446B1/en active Active
- 2011-04-19 BR BR112012026471A patent/BR112012026471A2/pt not_active IP Right Cessation
- 2011-04-19 US US13/066,590 patent/US9193969B2/en active Active
- 2011-04-20 AR ARP110101361A patent/AR083715A1/es not_active Application Discontinuation
-
2015
- 2015-11-23 US US14/949,490 patent/US10071163B2/en active Active
-
2017
- 2017-06-30 AU AU2017204529A patent/AU2017204529A1/en not_active Abandoned
-
2019
- 2019-06-04 AU AU2019203887A patent/AU2019203887B2/en active Active
-
2020
- 2020-04-15 AU AU2020202533A patent/AU2020202533B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012149042A (ru) | Конъюгат (варианты), способ лечения заболеваний нервной системы (варианты), способ визуализации клетки, диагностическое средство, амидные соединения (варианты), способ получения конъюгата и способы получения амидных соединений | |
| JP6126009B2 (ja) | α−シヌクレイン発現の調節 | |
| EP3394259B1 (en) | Compositions and methods for decreasing tau expression | |
| EP2911695B1 (en) | Compositions and methods for the treatment of parkinson disease by the selective delivery of oligonucleotide molecules to specific neuron types | |
| US20250051766A1 (en) | Treatment of neurological diseases using modulators of unc13a gene transcripts | |
| CN116655715B (zh) | 一种GalNAc衍生物、缀合物、组合物以及它们的用途 | |
| EP4441226A2 (en) | Splice switcher antisense oligonucleotides with modified backbone chemistries | |
| JPWO2019022196A1 (ja) | 一本鎖オリゴヌクレオチド | |
| WO2022211129A1 (ja) | Ａｔｎ１のアンチセンスオリゴヌクレオチド誘導体 | |
| US20230235332A1 (en) | Treatment of neurological diseases using modulators of gene transcripts | |
| WO2024249791A2 (en) | Modified unc13a oligonucleotides | |
| WO2023102548A1 (en) | Treatment of neurological diseases using modulators of kcnq2 gene transcripts | |
| JP2021527649A5 (enExample) | ||
| CN119452086A (zh) | 具有修饰的主链化学的gapmer反义寡核苷酸 | |
| WO2023102227A2 (en) | Treatment of neurological diseases using modulators of smn2 gene transcripts | |
| US20200216845A1 (en) | Antisense oligonucleotides for modulating rela expression | |
| HK40121031A (zh) | 具有经修饰的主链化学的剪接转换器反义寡核苷酸 | |
| US20190367920A1 (en) | Antisense oligonucleotides for modulating nfkb1 expression | |
| CN103025357B (zh) | 选择性递送寡核苷酸分子至特定神经元类的组合物和方法 | |
| HK40121931A (zh) | 具有修饰的主链化学的gapmer反义寡核苷酸 | |
| IL313204A (en) | Methods for the synthesis of factor D complement inhibitors | |
| CN116528878A (zh) | 使用基因转录物调控剂治疗神经学疾病 |